Participation on March 30, 2012 (according to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).
Brussels (Belgium), April 5, 2012 - 7.30 p.m. (CET) - regulated information - Pharmahold SA (having its registered offices at Boulevard du Prince Henri 9b, 1724 Luxemburg), its subsidiary Cosylva SA (having its registered offices at Rue de la Chancellerie 2 bte 1, 1000 Brussels) and Compar Finance SA (having its registered offices at Rue Royale 97, 1000 Brussels), acting in concert, each have sold all their shares, totaling 7,065,830 UCB shares with voting rights on March 30, 2012, which means that Pharmahold SA (taking into account the holding of Cosylva SA) and Compar Finance SA falling jointly below the statutory threshold of 3% for notification.
UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608
For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, antje.witte@ucb.com
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global
biopharmaceutical company focused on the discovery and
development of innovative medicines and solutions to
transform the lives of people living with severe diseases
of the immune system or of the central nervous system. With
more than 8 000 people in about 40 countries, the company
generated revenue of EUR 3.2 billion in 2011. UCB is listed
on Euronext Brussels (symbol: UCB).
UCB Forward-looking statements
This press release contains forward-looking statements
based on current plans, estimates and beliefs of
management. All statements, other than statements of
historical fact, are statements that could be deemed
forward-looking statements, including estimates of
revenues, operating margins, capital expenditures, cash,
other financial information, expected legal, political,
regulatory or clinical results and other such estimates and
results. By their nature, such forward-looking statements
are not guarantees of future performance and are subject to
risks, uncertainties and assumptions which could cause
actual results to differ materially from those that may be
implied by such forward-looking statements contained in
this press release. Important factors that could result in
such differences include: changes in general economic,
business and competitive conditions, the inability to
obtain necessary regulatory approvals or to obtain them on
acceptable terms, costs associated with research and
development, changes in the prospects for products in the
pipeline or under development by UCB, effects of future
judicial decisions or governmental investigations, product
liability claims, challenges to patent protection for
products or product candidates, changes in laws or
regulations, exchange rate fluctuations, changes or
uncertainties in tax laws or the administration of such
laws and hiring and retention of its employees. UCB is
providing this information as of the date of this press
release and expressly disclaims any duty to update any
information contained in this press release, either to
confirm the actual results or to report a change in its
expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
distributed by |